Azurity Pharmaceuticals obtains FDA OK for Xifyrm
Azurity Pharmaceuticals has received permission from the Food and Drug Administration for Xifyrm (meloxicam injection), an IV non-steroidal anti-inflammatory drug that offers once daily dosing.
Xifyrm is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.
Xifyrm provides a non-opioid analgesic in a 30mg/mL vial for IV bolus injection over 15 seconds. Because of delayed onset of analgesia, Xifyrm alone is not recommended for use when rapid onset of analgesia is required, Azurity said.
[Read more: CutisPharma renames to Azurity Pharmaceuticals alongside Silvergate acquisition]
"Xifyrm demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management," said Ron Scarboro, CEO at Azurity Pharmaceuticals.
[Read more: Azurity Pharmaceuticals gets FDA OK for Eprontia]
Scarboro added, "Xifyrm addresses an important clinical need, especially for patients requiring a non-opioid component to multimodal analgesia strategies."